The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

17 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
49
Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEd prenyl binding site.EBI
Max Planck Institute of Molecular Physiology
20
Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells.EBI
Shanghai University
20
Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors.EBI
Purdue University
22
An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth.EBI
University of Luxembourg
4
Hydrophobic tag-based protein degradation: Development, opportunity and challenge.EBI
China Pharmaceutical University
14
Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).EBI
East China University of Science and Technology
33
"Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.EBI
Bioinnovation Institute
147
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.EBI
Central South University
14
Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.EBI
Second Military Medical University
36
Discovery of MEBI
Chiesi Farmaceutici
23
Fragment-Based Discovery of Novel Allosteric MEK1 Binders.EBI
AstraZeneca
13
Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.EBI
Second Military Medical University
17
Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.EBI
Janssen Research & Development
25
Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction.EBI
Chinese Academy of Sciences
30
Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.EBI
Second Military Medical University
17
Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.EBI
Second Military Medical University
110
Inhibiting agents for Bruton's tyrosine kinaseBDB
Biogen Ma